MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Xenon Pharmaceuticals Inc

Ouvert

SecteurSoins de santé

33.26 0.82

Résumé

Variation du prix de l'action

24h

Actuel

Min

32.94

Max

33.7

Chiffres clés

By Trading Economics

Revenu

638K

-65M

Ventes

7.5M

7.5M

BPA

-0.83

Marge bénéficiaire

-867.293

Employés

316

EBITDA

4.1M

-73M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+65.81% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-344M

2.4B

Ouverture précédente

32.44

Clôture précédente

33.26

Sentiment de l'Actualité

By Acuity

50%

50%

157 / 375 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 juil. 2025, 23:45 UTC

Acquisitions, Fusions, Rachats

Orix Corp. USA to Buy Majority Stake in Hilco Global >8591.TO

3 juil. 2025, 23:42 UTC

Market Talk

Gold Edges Higher Amid U.S. Fiscal-Deficit Concerns -- Market Talk

3 juil. 2025, 23:41 UTC

Market Talk

Nikkei May Rise After Solid U.S. Jobs Data -- Market Talk

3 juil. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juil. 2025, 23:15 UTC

Market Talk
Acquisitions, Fusions, Rachats

Beach Energy Could Smooth Path to Santos Takeover Approval -- Market Talk

3 juil. 2025, 22:59 UTC

Market Talk

Uranium Market About to Enter Lull -- Market Talk

3 juil. 2025, 22:58 UTC

Market Talk

Value Emerging in Diversified Miners Despite Headwinds -- Market Talk

3 juil. 2025, 22:47 UTC

Market Talk

Australian Household Spending Numbers Key Ahead of RBA Meeting -- Market Talk

3 juil. 2025, 22:21 UTC

Résultats

This Summer's Big TV Hit Brings Back Soap Opera Memories -- Barrons.com

3 juil. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 juil. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

3 juil. 2025, 20:41 UTC

Market Talk

KKR Seen As Benefiting From Stabilizing Markets -- Market Talk

3 juil. 2025, 20:41 UTC

Market Talk

Global Equities Roundup: Market Talk

3 juil. 2025, 19:28 UTC

Market Talk

Oil Gives Back Some Gains With OPEC+ in View -- Market Talk

3 juil. 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Retreats Ahead of Long Weekend -- Market Talk

3 juil. 2025, 18:34 UTC

Market Talk

Gold Has Winning Week, But Down Day -- Market Talk

3 juil. 2025, 18:18 UTC

Market Talk

Anticipation for Trump Address Gives Grain Traders Optimism -- Market Talk

3 juil. 2025, 18:06 UTC

Market Talk

Global Equities Roundup: Market Talk

3 juil. 2025, 18:06 UTC

Market Talk

Brazilian Stocks, Bonds Expected to Benefit From Benign Macro Trends -- Market Talk

3 juil. 2025, 17:27 UTC

Market Talk

U.S. Oil Rig Count Continues to Slide -- Market Talk

3 juil. 2025, 16:55 UTC

Résultats

Travel Stocks Could Offer Investors a Glorious -2-

3 juil. 2025, 16:55 UTC

Résultats

Travel Stocks Could Offer Investors a Glorious Trip, This Analyst Says -- Barrons.com

3 juil. 2025, 16:20 UTC

Market Talk

Correction to Health Care Roundup: Market Talk

3 juil. 2025, 16:15 UTC

Market Talk

Oil Futures Lose Ground in Choppy Pre-Holiday Trade -- Market Talk

3 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 juil. 2025, 16:05 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juil. 2025, 16:05 UTC

Market Talk

Gold Futures Fall Following Jobs Report -- Market Talk

3 juil. 2025, 15:47 UTC

Résultats

Honeywell Stock Is on a Roll. It Looks Ready to Break Out. -- Barrons.com

3 juil. 2025, 15:36 UTC

Résultats
Acquisitions, Fusions, Rachats

Why It's Time to Buy This Rocks and Cement Spinoff Stock You've Probably Never Heard Of -- Barrons.com

Comparaison

Variation de prix

Xenon Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

65.81% hausse

Prévisions sur 12 Mois

Moyen 55.33 USD  65.81%

Haut 65 USD

Bas 47 USD

Basé sur 15 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

15 ratings

15

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

34.81 / 38.24Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

157 / 375Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.